As of June 30, 2026, Dong Wha Pharm Co., Ltd. carries a market capitalization of 138.87B, placing it among publicly traded companies globally. Its enterprise value stands at 250.61B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 138.87B |
| Enterprise Value | 250.61B |
Dong Wha Pharm Co., Ltd.'s next confirmed earnings release is scheduled for November 18, 2026.
| Earnings Date | 11/18/2026 |
As of June 30, 2026, Dong Wha Pharm Co., Ltd. has 27.72M shares outstanding.
| Shares Outstanding | 27.72M |
As of June 30, 2026, Dong Wha Pharm Co., Ltd. trades at a trailing price-to-earnings ratio of 7.68. The price-to-sales ratio is 0.27, and the price-to-book ratio stands at 0.35.
| PE Ratio | 7.68 |
| PS Ratio | 0.27 |
| PB Ratio | 0.35 |
| P/TBV Ratio | 0.44 |
| P/FCF Ratio | -31.07 |
| P/OCF Ratio | 5.07 |
As of June 30, 2026, Dong Wha Pharm Co., Ltd. trades at an EV/EBITDA multiple of 6.05 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.49 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 13.27 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 250.61B versus a market cap of 138.87B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 0.49 |
| EV / EBITDA | 6.05 |
| EV / EBIT | 13.27 |
As of June 30, 2026, Dong Wha Pharm Co., Ltd. maintains a current ratio of 1.22, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 29.76, indicating elevated leverage, while an interest coverage ratio of 7.34 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.22 |
| Quick Ratio | 0.17 |
| Debt / Equity | 29.76 |
| Debt / EBITDA | 2.99 |
| Interest Coverage | 7.34 |
Over the twelve months ended June 30, 2026, Dong Wha Pharm Co., Ltd. posted a return on equity (ROE) of 4.69, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 2.79, measuring how efficiently the asset base is converted into earnings. The company generates approximately 615.03M in revenue per employee across its workforce of 834.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.92 indicates how many times Dong Wha Pharm Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | 4.69 |
| Return on Assets (ROA) | 2.79 |
| Revenue Per Employee | 615.03M |
| Employee Count | 834.50 |
| Inventory Turnover | 2.92 |
Over the twelve months ended June 30, 2026, Dong Wha Pharm Co., Ltd. recorded an income tax benefit of -2.63B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 11.99B, leaving 18.08B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.
| Income Tax | -2.63B |
As of the close on November 17, 2026, Dong Wha Pharm Co., Ltd.'s stock has declined approximately 22.68% over the past 52 weeks. The 50-day moving average sits at 5,225.60, while the 200-day moving average is 5,537.10.
| 52-Week Price Change | -22.68% |
| 50-Day Moving Average | 5,225.60 |
| 200-Day Moving Average | 5,537.10 |
Over the twelve months ended June 30, 2026, Dong Wha Pharm Co., Ltd. generated 513.24B in revenue and converted that into 18.08B in net income, yielding earnings per share of 527.68. EBITDA reached 41.42B, while operating income came in at 18.89B.
| Revenue | 513.24B |
| Gross Profit | 226.24B |
| Operating Income | 18.89B |
| Pretax Income | 11.99B |
| Net Income | 18.08B |
| EBITDA | 41.42B |
| EBIT | 18.89B |
| Earnings Per Share (EPS) | 527.68 |
As of June 30, 2026, Dong Wha Pharm Co., Ltd. holds 32.49B in cash and equivalents against 123.64B in total debt, resulting in a net debt position of 85.06B. Total book value stands at 394.87B, with working capital of 43.18B providing operational flexibility.
| Cash & Cash Equivalents | 32.49B |
| Total Debt | 123.64B |
| Net Debt | 85.06B |
| Equity (Book Value) | 394.87B |
| Book Value Per Share | 14,246.17 |
| Working Capital | 43.18B |
Dong Wha Pharm Co., Ltd. produced 27.37B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -31.83B in capital expenditures, free cash flow totaled -4.47B - equivalent to -161.23 per share.
| Operating Cash Flow | 27.37B |
| Capital Expenditures | -31.83B |
| Free Cash Flow | -4.47B |
| FCF Per Share | -161.23 |
Over the twelve months ended June 30, 2026, Dong Wha Pharm Co., Ltd. posted a gross margin of 44.08, reflecting its pricing power and cost economics. The operating margin of 3.68 and net profit margin of 3.52 provide insight into operational efficiency.
| Gross Margin | 44.08 |
| Operating Margin | 3.68 |
| Pretax Margin | 2.34 |
| Profit Margin | 3.52 |
| EBITDA Margin | 8.07 |
Over the twelve months ended June 30, 2026, Dong Wha Pharm Co., Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -3.22: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -2.89, meaning Dong Wha Pharm Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -2.89 |
| FCF Yield | -3.22 |
Dong Wha Pharm Co., Ltd.'s most recent stock split took place on July 20, 2009 with a 1:5 split ratio.
| Last Split Date | 7/20/2009 |
| Split Ratio | 1:5 |
As of June 30, 2026, Dong Wha Pharm Co., Ltd. has an Altman Z-Score of 2.31, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.31 |
Already premium?